# Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS

Source: https://onco.cc/trials/nct03187288/  
OnCo record `nct03187288` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of CFI-400945 run by University Health Network, Toronto, completed.

## Summary

Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS is a phase 1 interventional study registered as NCT03187288 by University Health Network, Toronto, with 13 participants enrolled, started 2018-05-25. Conditions recorded: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Relapsed Cancer and Refractory Cancer. Interventions recorded: CFI-400945 Fumarate.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03187288
- Phase: 1
- Setting: An Open-Label, Dose Escalation, Safety and Pharmacokinetic Study of CFI-400945 Fumarate Administered Orally to Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Sponsor: University Health Network, Toronto
- Enrolled: 13

## Sources

- ClinicalTrials.gov NCT03187288: https://clinicaltrials.gov/study/NCT03187288

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)
- drugs: [CFI-400945](https://onco.cc/drugs/cfi-400945/)
- companies: [Treadwell Therapeutics](https://onco.cc/companies/treadwell-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct03187288.json